Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Cancer Highlights | The Drug Target Atlas of Apoptopic Drugs in Oncology

The Drug Target Atlas of Apoptopic Drugs in Oncology

The ultimate goal of cancer research is to learn how to make cancer cells selectively die. Apoptosis is the type of death about whose genetically controlled pathways we know the most.

Apoptotic cell death can be triggered by many different cellular stimuli, resulting in activation of apoptotic signaling pathways including extrinsic, intrinsic, and mitochondrial pathways. The plethora of new potential therapeutic drugs has made selection and validation of novel molecular targets of paramount importance.

First in place, BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. This report, The Drug Target Atlas of Apoptopic Drugs in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new apoptopic drugs in oncology.

In the report, BioSeeker reports on 90 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 114 apoptopic drugs designed for the treatment of 48 different cancer indications. The highest degree of distinctiveness among apoptopic drugs is achieved by sorting each of them according to targeted cancer indication, drug target mix, and drug compound type. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of apoptopic drugs. No less than 452 protein-protein interactions were recognized among 96 of the 119 included apoptopic drug targets.

The report by the numbers

* 250+ pages, with almost a hundred different tables. Includes more than 1,500 active links to related resources on the Internet

* 114 apoptopic drugs, under development by 87 investigators, are included, covering more than 430 developmental projects in cancer

* 119 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other apoptopic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.

* 90 Unique drug target combinations of apoptopic drugs

* 452 protein-protein interactions among apoptopic drug targets

Extensive pathway analysis of drug targets

This report serves as a serious reference for any professional interested in the development of oncology drug targets and the selection/validation of targeting strategies.

Pages: 250+ February 2008
Table of Contents
Price: $3,800.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions